Meeting
2022 ASCO Annual Meeting
An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC).
Authors
Aiwu Ruth He
Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC
Aiwu Ruth He , Filip Banovac , Renuka V. Iyer , Michael Petroziello , Daniel Brown , Laura Williams Goff , Richard D. Kim , Nainesh Parikh , Beau Toskich , Kevin Kim , Yixing Jiang , Suvranu Ganguli , Matthew H. Kulke , Samantha Ann Armstrong , Matthew Johnson , Rachna T. Shroff , Gregory Woodhead
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT04541173
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4177)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4177
Abstract #
TPS4177
Poster Bd #
154a
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
First Author: Aiwu Ruth He
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
First Author: Daneng Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
First Author: Kevin Kim
Poster
2023 ASCO Annual Meeting
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
First Author: Tanios S. Bekaii-Saab